Mild cognitive impairment (MCI) is frequent in elderly and a risk factor for dementia. Both insomnia and increased cortisol levels are risk factors for MCI.
Objective:
We examined cross-sectionally whether increased cortisol levels are associated with short sleep duration (SSD) and/or the insomnia short sleep duration (ISS) phenotype, in elderly with MCI.
Methods:
One hundred twenty-four participants with MCI and 84 cognitively non-impaired controls (CNI)≥60 years underwent medical history, physical examination, neuropsychiatric evaluation, neuropsychological testing, 3-day actigraphy, assessment of subjective insomnia symptoms, and a single morning plasma cortisol level. The short sleep phenotypes were defined by sleep efficiency below the median of the entire sample (i.e.,≤81%) with at least one insomnia symptom (ISS) or without (SSD). ANOVA models were used to compare the various sleep phenotypes to those who did not present either short sleep or insomnia symptoms [non-insomnia (NI)].
Results:
MCI participants had higher cortisol levels compared to the CNI group (p = 0.009). MCI participants with insomnia (n = 44) or SSD (n = 38) had higher cortisol levels compared to the NI group (n = 42; p = 0.014 and p = 0.045, respectively). Furthermore, MCI participants with ISS phenotype but not those with insomnia with normal sleep duration had higher cortisol levels compared to NI (p = 0.011 and p = 0.4, respectively). Both linear trend analyses showed that cortisol reached the highest levels in the ISS phenotype.
Conclusion:
The ISS and SSD phenotypes are associated with increased cortisol levels in elderly with MCI. Improving sleep quality and duration and decreasing cortisol levels may delay further cognitive decline.
MerlinoG, PianiA, GigliGL, CancelliI, RinaldiA, BaroselliA, SerafiniA, ZanchettinB, ValenteM (2010) Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: A population-based study. Sleep Med11, 372–377.
ZaganasIV, SimosP, BastaM, KapetanakiS, PanagiotakisS, KoutentakiI, FountoulakisN, BertsiasA, DuijkerG, TzirakiC, ScarmeasN, PlaitakisA, BoumpasD, LionisC, VgontzasAN (2019) The Cretan Aging Cohort: Cohort description and burden of dementia and mild cognitive impairment. Am J Alzheimers Dis Other Demen34, 23–33.
7.
YannakouliaM, KontogianniM, ScarmeasN (2015) Cognitive health and Mediterranean diet: Just diet or lifestyle pattern?Ageing Res Rev20, 74–78.
8.
LupienSJ, de LeonM, de SantiS, ConvitA, TarshishC, NairNP, ThakurM, McEwenBS, HaugerRL, MeaneyMJ (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci1, 69–73.
9.
SapolskyRM, KreyLC, McEwenBS (1986) The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev7, 284–301.
10.
VgontzasAN, ZoumakisM, BixlerEO, LinHM, ProloP, Vela-BuenoA, KalesA, ChrousosGP (2003) Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: Physiologic and therapeutic implications. J Clin Endocrinol Metab88, 2087–2095.
11.
McEwenBS (2002) Sex, stress and the hippocampus: Allostasis, allostatic load and the aging process. Neurobiol Aging23, 921–939.
12.
ChrousosGP (2009) Stress and disorders of the stress system. Nat Rev Endocrinol5, 374–381.
13.
RossIL, JonesJ, BlockmanM (2018) We are tired of ‘adrenal fatigue’. S Afr Med J108, 724–725.
14.
LupienSJ, McEwenBS, GunnarMR, HeimC (2009) Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci10, 434–445.
ArnstenAF (2009) Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci10, 410–422.
17.
StombyA, BoraxbekkCJ, LundquistA, NordinA, NilssonLG, AdolfssonR, NybergL, OlssonT (2016) Higher diurnal salivary cortisol levels are related to smaller prefrontal cortex surface area in elderly men and women. Eur J Endocrinol175, 117–126.
18.
LeeBK, GlassTA, McAteeMJ, WandGS, Bandeen-RocheK, BollaKI, SchwartzBS (2007) Associations of salivary cortisol with cognitive function in the Baltimore memory study. Arch Gen Psychiatry64, 810–818.
19.
ComijsHC, GerritsenL, PenninxBW, BremmerMA, DeegDJ, GeerlingsMI (2010) The association between serum cortisol and cognitive decline in older persons. Am J Geriatr Psychiatry18, 42–50.
20.
GeerlingsMI, SigurdssonS, EiriksdottirG, GarciaME, HarrisTB, GudnasonV, LaunerLJ (2015) Salivary cortisol, brain volumes, and cognition in community-dwelling elderly without dementia. Neurology85, 976–983.
PoppJ, WolfsgruberS, HeuserI, PetersO, HüllM, SchröderJ, MöllerHJ, LewczukP, SchneiderA, JahnH, LuckhausC, PerneczkyR, FrölichL, WagnerM, MaierW, WiltfangJ, KornhuberJ, JessenF (2015) Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer’s type. Neurobiol Aging36, 601–607.
23.
WolfOT, ConvitA, ThornE, de LeonMJ (2002) Salivary cortisol day profiles in elderly with mild cognitive impairment. Psychoneuroendocrinology27, 777–789.
Arsenault-LapierreG, ChertkowH, LupienS (2010) Seasonal effects on cortisol secretion in normal aging, mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging31, 1051–1054.
26.
ZhengB, TalR, YangZ, MiddletonL, Udeh-MomohC (2020) Cortisol hypersecretion and the risk of Alzheimer’s disease: A systematic review and meta-analysis. Ageing Res Rev64, 101171.
27.
OuanesS, PoppJ (2019) High cortisol and the risk of dementia and Alzheimer’s disease: A review of the literature. Front Aging Neurosci11, 43.
28.
NeikrugAB, Ancoli-IsraelS (2010) Sleep disorders in the older adult- a mini-review. Gerontology56, 181–189.
VgontzasAN, LiaoD, BixlerEO, ChrousosGP, Vela-BuenoA (2009) Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep32, 491–497.
31.
KundelV, ReidM, FayadZ, AyappaI, ManiV, RueschmanM, RedlineS, SheaS, ShahN (2021) Sleep duration and vascular inflammation using hybrid positron emission tomography/magnetic resonance imaging: Results from the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Sleep Med17, 2009–2018.
32.
AbdallaM, SchwartzJE, CorneliusT, ChangBP, AlcántaraC, ShechterA (2020) Objective short sleep duration and 24-hour blood pressure. Int J Cardiol Hypertens7, 100062.
33.
DomínguezF, FusterV, Fernández-AlviraJM, Fernández-FrieraL, López-MelgarB, Blanco-RojoR, Fernández-OrtizA, García-PavíaP, SanzJ, MendigurenJM, IbañezB, BuenoH, Lara-PezziE, OrdovásJM (2019) Association of sleep duration and quality with subclinical atherosclerosis. J Am Coll Cardiol73, 134–144.
McSorleyVE, BinYS, LauderdaleDS (2019) Associations of sleep characteristics with cognitive function and decline among older adults. Am J Epidemiol188, 1066–1075.
36.
BastaM, SimosP, BertsiasA, DuijkerG, ZaganasI, KoutentakiE, AnastasakiM, MavroidisG, KalomoiriG, PanagiotakisS, LionisC, VgontzasAN (2018) Association between insomnia symptoms and cognitive impairment in the Cretan Aging Cohort. Eur Geriatr Med9, 697–706.
37.
JelicicM, BosmaH, PondsRWH, Van BoxtelM, HouxPJ, JollesJ (2002) Subjective sleep problems in later life as predictors of cognitive decline. Int J Geriatr Psychiatry17, 73–77.
38.
CriccoM, SimonisickEM, FoleyDJ (2001) The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc49, 1185–1189.
39.
ShiL, ChenSJ, MaMY, BaoYP, HanY, WangYM, ShiJ, VitielloMV, LuL (2018) Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev40, 4–16.
40.
LengY, McEvoyCT, AllenIE, YaffeK (2017) Association of sleep-disordered breathing with cognitive function and risk of cognitive impairment: A systematic review and meta-analysis. JAMA Neurol74, 1237–1245.
41.
Fernandez-MendozaJ, VgontzasAN, LiaoD, ShafferML, Vela-BuenoA, BastaM, BixlerEO (2012) Insomnia with objective short sleep duration and incident hypertension: The Penn State cohort. Hypertension60, 929–935.
42.
VgontzasAN, LiaoD, PejovicS, CalhounS, KaratarakiM, BixlerEO (2009) Insomnia with objective short sleep duration is associated with type 2 diabetes: A population based study. Diabetes Care32, 1980–1985.
43.
VgontzasAN, LiaoD, PejovicS, CalhounS, KaratarakiM, BastaM, Fernández-MendozaJ, BixlerEO (2010) Insomnia with short sleep duration and mortality: The Penn State cohort. Sleep33, 1159–1164.
44.
VgontzasAN, Fernandez-MendozaJ, LiaoD, BixlerEO (2013) Insomnia with objective short sleep duration: The most biologically severe phenotype of the disorder. Sleep Med Rev17, 241–254.
45.
BastaM, SimosP, VgontzasA, KoutentakiE, TzirakiS, ZaganasI, PanagiotakisS, KapetanakiS, FountoulakisN, LionisC (2019) Associations between sleep duration and cognitive impairment in MCI. J Sleep Res28, 12864.
46.
FountoulakisKN, TsolakiM, ChantziH, KazisA (2000) Mini Mental State Examination (MMSE): A validation study in Greece. Am J Alzheimers Dis Other Demen15, 342–345.
47.
DardiotisE, KosmidisMH, YannakouliaM, HadjigeorgiouGM, ScarmeasN (2014) The Hellenic Longitudinal Investigation of Aging and Diet (HELIAD): Rationale, study design, and cohort description. Neuroepidemiology43, 9–14.
48.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundLO, NordbergA, BäckmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
49.
BixlerEO, VgontzasAN, LinHM, Vela-BuenoA, KalesA (2002) Insomnia in Central Pennsylvania. J Psychosom Res53, 589–592.
50.
VgontzasAN, TsigosC, BixlerEO, StratakisCA, ZachmanK, KalesA, Vela-BuenoA, ChrousosGP (1998) Chronic insomnia and activity of the stress system: A preliminary study. J Psychosom Res45, 21–31.
51.
VgontzasAN, BixlerEO, LinHM, ProloP, MastorakosG, Vela-BuenoA, KalesA, ChrousosGP (2001) Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab86, 3787–3794.
52.
Fernandez-MendozaJ, VgontzasAN (2013) Insomnia and its impact on physical and mental health. Curr Psychiatry Rep15, 418.
53.
BarilAA, BeiserAS, SanchezE, MysliwiecV, RedlineS, GottliebDJ, O’ConnorGT, GonzalesMM, HimaliD, SeshadriS, HimaliJJ, PaseMP (2022) Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype. Alzheimers Dement18, 408–421.
54.
OlaitheM, ReeM, McArdleN, DonaldsonS, PushpanathanM, EastwoodPR, BucksRS (2021) Cognitive dysfunction in insomnia phenotypes: Further evidence for different disorders. Front Psychiatry12, 688672.
55.
BastaM, KoutentakiE, VgontzasA, ZaganasI, VogiatziE, GounaG, BourbouliM, PanagiotakisS, KapetanakiS, Fernandez-MendozaJ, SimosP (2020) Objective daytime napping is associated with disease severity and inflammation in patients with mild to moderate dementia. J Alzheimers Dis74, 803–815.
56.
VgontzasAN, PuzinoK, Fernandez-MendozaJ, KrishnamurthyVB, BastaM, BixlerEO (2020) Effects of trazodone versus cognitive behavioral therapy in the insomnia with short sleep duration phenotype: A preliminary study. J Clin Sleep Med16, 2009–2019.
57.
RodenbeckA, CohrsS, JordanW, HuetherG, RütherE, HajakG (2003) The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl)170, 423–428.
58.
LaAL, WalshCM, NeylanTC, VosselKA, YaffeK, KrystalAD, MillerBL, KarageorgiouE (2019) Long-term trazodone use and cognition: A potential therapeutic role for slow-wave sleep enhancers. J Alzheimers Dis67, 911–921.
59.
BrauerR, LauWCY, HayesJF, ManKKC, OsbornDPJ, HowardR, KimJ, WongICK (2019) Trazodone use and risk of dementia: A population-based cohort study. PLoS Med16, e1002728.
60.
MikkelsenJD, SødermanA, KissA, MirzaN (2005) Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis. Eur J Pharmacol519, 223–230.
61.
MikkelsenJD, BundzikovaJ, LarsenMH, HansenHH, KissA (2008) GABA regulates the rat hypothalamic-pituitary-adrenocortical axis via different GABA-A receptor alpha-subtypes. Ann N Y Acad Sci1148, 384–392.
62.
PechnickRN, LacayoLM, ManaloCM, BholatY, SpivakI (2011) Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in the rat. Eur J Pharmacol661, 22–26.
63.
BixlerEO, VgontzasAN, Ten HaveT, TysonK, KalesA (1998) Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med157, 144–148.
